About The Study: In this randomized clinical trial of 345 patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound were both common after a standard 5-day course of antiviral treatment with either VV116 or nirmatrelvir-ritonavir. Prolongation of treatment duration might be investigated to reduce COVID-19 rebound.
Authors: Yufang Bi, M.D., and Yiping Xu, M.Sc., of the Shanghai Jiao Tong University School of Medicine in Shanghai, China, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.1765)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.1765?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=031324
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open